Short-Term Morphofunctional Changes in Previously Treated Neovascular AMD Eyes Switched to Brolucizumab

医学 阿柏西普 眼科 血管抑制剂 脉络膜新生血管 血管性 视力 黄斑变性 贝伐单抗 外科 化疗
作者
Pasquale Viggiano,Maria Oliva Grassi,Giacomo Boscia,Mariagrazia Pignataro,Giovanni Petruzzella,Enrico Borrelli,Teresa Molfetta,Giovanni Alessio,Francesco Boscia
出处
期刊:Journal of Clinical Medicine [Multidisciplinary Digital Publishing Institute]
卷期号:11 (19): 5517-5517 被引量:7
标识
DOI:10.3390/jcm11195517
摘要

The purpose of the study is to explore the morphofunctional fluctuations in eyes treated for neovascular AMD (nAMD) when treatment is switched from aflibercept or ranibizumab to brolucizumab. A total of 31 eyes of 31 patients with nAMD with type 1 macular neovascularization (MNV) were included. All patients were imaged using spectral domain optical coherence tomography (SD-OCT). The OCT acquisition was performed at the following visits: (i) “T1 visit” corresponding to the last follow-up examination in which an intravitreal injection of aflibercept or ranibizumab was performed before switching to brolucizumab because of the lack of improvement and (ii) “T2 visit” corresponding to the examination performed 1 month after T1, the latter visit corresponding to the day when a switch to brolucizumab injection was performed, (iii) and 1 month after the latter injection “(T3)”. The main outcome measures were: (1) central macular thickness (CMT), (2) choroidal vascularity index (CVI), (3) subfoveal choroidal thickness (CT), and best-corrected visual acuity (BCVA). Functional outcome showed significant differences at each time. Mean ± SD BCVA was 0.43 ± 0.12 LogMAR at T1 and 0.56 ± 0.16 LogMAR at T2 (p = 0.038). A significant improvement in BCVA was displayed at T3 (0.34 ± 0.21 LogMAR) as compared with T2 (p = 0.019). CMT analysis showed fluctuations three times. In detail, T2 displayed a thicker CMT in comparison with T1, although not statistically significant (p = 0.12). Contrariwise, T3 showed a thinner CMT in comparison with T2 (p = 0.002). Analyzing CVI among the three different times, the luminal choroidal area (LCA) and total choroidal area (TCA) showed significantly different values before and after switching to brolucizumab. T2 showed a significant reduction in both vessel lumen and total area compared with T1 (p = 0.032 and p = 0.046, respectively). Moreover, T3 showed a greater value of both LCA and TCA in comparison with T2 (p = 0.008 and p = 0.01, respectively). CT did not show significant differences at each time (p > 0.05). Our results reported early experiences on morphofunctional fluctuations in patients with nAMD who switched to brolucizumab. The anatomical impact of brolucizumab administration appears to result in choroidal vascular enlargement, accompanied by the resolution of subretinal fluid (SRF) and intraretinal fluid (IRF).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Stageruner完成签到,获得积分10
刚刚
kiyo_v完成签到,获得积分10
刚刚
黄超超发布了新的文献求助10
1秒前
落寞剑成完成签到 ,获得积分10
1秒前
七子完成签到,获得积分10
1秒前
klio完成签到 ,获得积分10
2秒前
zzx396完成签到,获得积分0
3秒前
one完成签到 ,获得积分10
4秒前
十五完成签到,获得积分10
4秒前
ptjam完成签到 ,获得积分10
5秒前
神勇的晟睿完成签到 ,获得积分10
6秒前
6秒前
曾珍完成签到 ,获得积分10
6秒前
Muhi完成签到,获得积分10
6秒前
6秒前
自带蓝牙的土豆完成签到 ,获得积分10
7秒前
青羽落霞完成签到 ,获得积分10
8秒前
抹颜完成签到,获得积分10
9秒前
量子星尘发布了新的文献求助10
13秒前
胡图图完成签到,获得积分10
14秒前
睡觉大王完成签到 ,获得积分10
15秒前
16秒前
16秒前
17秒前
17秒前
22秒前
玩命的十三完成签到 ,获得积分10
22秒前
寂寞的诗云完成签到,获得积分10
24秒前
我爱科研完成签到 ,获得积分10
24秒前
25秒前
Bin_Liu发布了新的文献求助10
26秒前
She完成签到,获得积分10
26秒前
29秒前
Raki完成签到,获得积分10
30秒前
22完成签到 ,获得积分10
30秒前
Echo_1995完成签到,获得积分10
33秒前
徐慕源完成签到,获得积分10
33秒前
able发布了新的文献求助10
34秒前
呜呜完成签到 ,获得积分10
35秒前
35秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038184
求助须知:如何正确求助?哪些是违规求助? 3575908
关于积分的说明 11373872
捐赠科研通 3305715
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892662
科研通“疑难数据库(出版商)”最低求助积分说明 815022